Cost-effectiveness threshold (CET) can judge the economy efficiency of different medical intervention measures. It is an important reference standard for medical insurance directory access. It is also an important pharmacoeconomic evidence for the lack of medical insurance access negotiations for innovative drugs in China. This paper summarizes the experience of the application of CET in the world and lays a foundation for the determination and application of innovative drug CET in China. CET is an important basis for the selection of health interventions in many countries. It is mainly divided into implicit threshold and explicit threshold, most countries use implicit threshold for decision-making. The per capita GDP multiple is the CET mode selected by most countries. In the face of different application scenarios of innovative drugs, such as rare diseases treatment, end-stage treatment and disease treatment of different severity, countries make adjustments to different degrees on the basis of general CET. It is not clear whether CET is used in China's health decision-making. It is suggested to explore the threshold and level in line with China's national conditions on the basis of international experience, focus on exploring the application of hidden threshold in medical insurance access and preferential policies for rare diseases and end-of-life drugs and actively promote the scientific determination of CET in China.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |